Stifel Financial Corp SF

1919 Investment Counsel, LLC ("1919"), a subsidiary of Stifel Financial Corp. ("Stifel"), is proud to announce its inclusion in Barron's 2026 Top 100 RIA Firms list. Ranked No. 33 nationally, 1919 has earned a place on the list for the seventh consecutive year, reflecting the firm's continued commitment to helping clients achieve their long-term financial goals.

Stifel, the broker, has kept its ‘buy’ rating and CHF25 target price on Santhera Pharmaceuticals (SIX:SANN, OTC:SPHDF, FRA:S3F0), the Swiss neuromuscular drugmaker, after first-half group revenue doubled to CHF48.3 million. The company left its 2026 guidance of CHF80 million to CHF90 million...

Microsoft Stock Gets Surprise Upgrade as Stifel Sees Growth Back on Track

Microsoft has been the quiet name in the AI trade all year, but that just changed.

Investing.com -- Stifel has highlighted its top stock selection in the real estate investment trust sector, featuring First Industrial Realty Trust as the firm’s current favorite idea from its equity research analysts.

ST. LOUIS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today reported selected operating results for August 31, 2026, to provide timely information to investors on certain key performance metrics. Due to the limited nature of this data, a consistent correlation to earnings should not be assumed. Ronald J. Kruszewski, Chairman and Chief Executive Officer, said, “Total client assets and fee-based client assets reached record highs, increasing 12% and 17% year over year, ex

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that management will be participating in the Stifel 2026 Virtual Cardiometabolic Forum taking place on September 30, 2026. Stifel 202

Microsoft’s story may finally be gaining traction. Here’s why Stifel sees a path back to growth for MSFT.

Interest rates are rising again, inflation is still sticky, and suddenly the sleepy corner of brokerage cash and margin lending looks anything but boring. When the Fed pushes the benchmark rate to a range of 3.75% to 4%, every idle dollar in a brokerage account and every margin loan starts to matter more to investors and to the brokers themselves. This article walks through three US retail broker-dealer stocks that screen as exposed to these crosscurrents, and explains how higher-for-longer...

Microsoft stock momentum is expected to continue as OpenAI revenue contribution to Microsoft accelerates.

CAMBRIDGE, Mass., September 23, 2026--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum

GAITHERSBURG, Md., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET. A webcast of the fireside chat will be available via the Events section of the Altimmune website. About Altimmune Altimmune is a late clinic

NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on

Expect another earnings beat from Micron next week -- a smaller beat, but still a beat.

Stifel expects greater promotional activity in Western markets and a more challenging year-over-year gross margin comparison in the fiscal fourth quarter.

BRP now carries a higher Fair Value Estimate of CA$103.07, up from CA$97.22, which lines up more closely with the Street price targets that have been cited after the latest update. Recent analyst commentary reflects this shift, with more upbeat views tying higher targets to Q2 execution and product momentum, while cautious voices still highlight tariff and valuation risks. As you read on, you will see how this evolving narrative around BRP may shape the way you track the stock from here. Stay...

Plains GP Holdings is under fresh scrutiny as fair value in one key model shifts from about US$24.93 to about US$25.77, a move that brings price targets into slightly higher territory. Recent analyst research connects this change to the Silver Creek Midstream acquisition, updated Q2 assumptions and the company’s Permian crude exposure, with views ranging from more constructive to still cautious. As you read on, you will see how to track these moving parts and keep up with the evolving story...